Showing results (971-980 of 1,171) with videos related to

Sort By:
Pageof 118
Hepatology (Baltimore, Md.)|May 23, 2024
Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGITYunfan Sun, Tong Li, Lin Ding, et al.
Cancer Cell International|March 20, 2022
KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinomaZheng Gao, Jia-Feng Chen, Xiao-Gang Li, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|November 28, 2024
New chapter in reform and development of organ donation and transplantation in China: Embracing past, grounding in national conditions, upholding steadfast belief, and looking forward to futureHong-Tao Zhao, Shu-Sen Zheng, Jia Fan, et al.
The Journal of Pathology|August 24, 2017
Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinomaLi-Jie Ma, Xiao-Ying Wang, Meng Duan, et al.
Oncotarget|December 18, 2015
Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneityJie-Yi Shi, Qingfeng Xing, Meng Duan, et al.
Cancer Cell|January 9, 2026
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancerZile Fu, Yuanli Song, Fen Liu, et al.
BMC Medicine|October 22, 2025
Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 StudyXiao-Yong Huang, Guo-Ming Shi, Zhi-Tao Zheng, et al.
Liver Cancer|June 16, 2023
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular CarcinomaZhenggang Ren, Guoliang Shao, Jie Shen, et al.
Journal of Hematology & Oncology|November 28, 2021
Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinomaJia-Cheng Lu, Peng-Fei Zhang, Xiao-Yong Huang, et al.
Theranostics|August 2, 2019
The miR-561-5p/CX3CL1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CX3CR1+ Natural Killer Cells InfiltrationEr-Bao Chen, Zheng-Jun Zhou, Kun Xiao, et al.
Pageof 118